Evaluate the Quality of Life of Patients With AMD

Inclusion criteria

• For the 2 populations studied

• Persons who have given consent to take part
• Persons aged 50 years or older
• Willing and able to attend all of the scheduled visits and evaluations
• Macular atrophy or drusen measuring at least 125μm or multiple drusens measuring at least 63μm
• Atrophic AMD diagnosed on OCT and by autofluorescence and OCT angiography by 2 independent experienced assessors
• Diagnosed for less than 3 years
• MAVC score ≥ 19 letters (Equivalent Snellen ≥ 20/400), by using a scale at an initial distance of 4m

For patients with secondary atrophic AMD

• Secondary atrophic AMD, defined by persistent atrophic AMD at 1 year after the last injection of an anti-angiogenic agent, and at least 2 years after the first injection.

Exclusion criteria

General criteria

• Persons without national health insurance cover
• Physical or mental disability ruling out participation
• Inability to sign the written consent form, adults under guardianship
• Any participation in a study involving an experimental drug during the previous 3 months (dietary supplements are authorised).
• Adults under guardianship

General medical history

• Uncontrolled AHT

Ophthalmological history

• Severe non-proliferative or proliferative diabetic retinopathy
• Uncontrolled glaucoma (defined as an intra-ocular pressure greater than 30mmHg despite treatment with an anti-glaucoma agent) or a history of filtration surgery
• Corneal disease that could impair vision
• Monogenic macular dystrophy or toxic maculopathy
• History of uveitis
• Amblyopia of the eye concerned
• Intraocular surgery in the 3 months preceding inclusion
• History of cornea transplantation in the studied eye
• Treatment affecting vision: chloroquine and hydroxychloroquine, phenothiazine, tamoxifen, interferon (93), external radiotherapy of the face and neck

Ophthalmological examination

• Significant cataract (LOCS III grade of 5 or above, annexe 5.) (94)
• Active infection in either eye
• Central anterior serous or active retinopathy in either eye
• Choroid neo-vascularisation
• Active serous retinal detachment
• Refractive error less than -15D or more than +10D